– Company entered into an Asset Purchase Agreement for substantially all of the operating assets of the Clinical Labs division
– Enzo Life Sciences reports revenue of $7.5 million, with Jan-23 revenue of $3.6M as the second highest monthly revenue in over 10 years
FARMINGDALE, NY, March 21, 2023 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, filed its Form 10-Q for the second quarter ended January 31, 2023 of Fiscal Year 2023 (Q2 FY23). Enzo Biochem will not be hosting a financial webcast or call for this most recent quarterly reporting period.
On March 16, 2023, Enzo Biochem announced that the Company entered into an Asset Purchase Agreement with respect to the sale of substantially all of the operating assets and assignment of certain liabilities which are necessary to operate the business of the Clinical Labs division. “This acquisition was part of an effort to evaluate strategic initiatives for Enzo Biochem that was initiated in 2022, in collaboration with the investment bank Jefferies LLC, said Hamid Erfanian, CEO of Enzo Biochem. By unlocking significant value for Enzo shareholders, the transaction positions Enzo to consider strategies to maximize the potential and value of the company’s remaining assets, including the Enzo Life Sciences segment.”
Second Quarter 2023 Revenue Results
Revenues reached $16.3M in the second quarter, a decrease of 52% compared to $34.0M in the second quarter of last year and a decrease of 11% sequentially compared to the first quarter of FY23. The decrease compared to Q2 FY22 was driven by the decline of COVID testing and timing of bulk product orders.
Q2 FY23 revenues for Enzo Life Sciences were $7.5 million. After adjusting for a bulk order in the prior year, Q2 FY23 revenues were near flat compared to Q2 FY22. Revenues grew 6% when compared to the sequential period of Q1 FY23, with Europe contributing approximately 20% growth. The January 2023 revenue was the second highest monthly revenue in over 10 years.
Q2 FY23 revenues for the Clinical Lab segment were $8.8 million, a decrease of 63% compared to the $23.7 million in the second quarter of last year, primarily impacted by the decline in COVID testing revenues. Non-COVID testing accessions grew 7% compared to the same period in the prior year, but those revenues declined due to payer and liquidation rate adjustments, as well as a charge to revenue due to a Medicaid audit.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies. For more information, please visit Enzo.com or follow Enzo Biochem on Twitter and LinkedIn.
Forward-Looking Statements
Except for historical information, the matters discussed in this release may be considered “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2022. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.
###
Enzo Biochem Contacts
For Enzo Biochem:
For Media:
For Investors:
Patricia Eckert, Interim CFO
631-755-5500
peckert@enzo.com
Lynn Granito
Berry & Company Public Relations
212-253-8881
lgranito@berrypr.com
Chris Calabrese
LifeSci Advisors, LLC
917-680-5608
ccalabrese@lifesciadvisors.com
Related Quotes
Everyone invests with the goal of generating big returns but it’s easy to get distracted by all the short-term noise generated on Wall Street. The key to investing success, according to Raymond James CIO Larry Adam, is to follow a few simple rules. One is to realize past performance does not necessarily guarantee future success. “History has shown that no single asset class has been a consistent winner year after year,” says Adam, “just as no single asset class remains at the bottom.” Secondly,
SmartAsset compares three of the largest investment companies based on usability, trade experience, offerings and cost. Learn more here.
Oil prices surged on Monday after Saudi Arabia and other OPEC+ oil producers announced a surprise round of output cuts, a potentially ominous sign for global inflation just days after a slowdown in U.S. price data had boosted market optimism. The change comes before a virtual meeting of an OPEC+ ministerial panel, which includes Saudi Arabia and Russia, and which had been expected to stick to 2 million bpd of cuts already in place until the end of 2023. The latest reductions could lift oil prices by $10 per barrel, the head of investment firm Pickering Energy Partners said on Sunday.
Tesla deliveries hit a new record but missed views again, How will TSLA stock react after breaking out Friday? China EV rivals also reported deliveries.
Bank stocks have been beaten down so much this year that they're now starting to look attractive.
When Credit Suisse opened its first office in Saudi Arabia in early 2021, Bruno Daher, the cigar-smoking head of Credit Suisse’s Middle East business, declared it a “key growth market”.
Recognizing the right stocks is a skill that every investor needs to learn, and the sheer volume of market data, on the main indexes, on individual stocks, on and from stock analysts, can present an intimidating barrier. Fortunately, there are tools to help. The Smart Score is a data collection and collation tool from TipRanks, using an AI-powered algorithm to sort the data on every stock according to a series of factors, 8 in all, that are known for their strong correlation with future share ou
Tesla on Sunday reported first quarter delivery and production numbers that topped estimates, indicating price cuts it initiated across the globe are boosting demand.
Bob Michele, the chief investment officer of JPMorgan Asset Management, has warned of an economic downturn, saying that markets are headed for a rally before an inevitable slowdown. In an interview with Bloomberg on Friday, Michele says risk assets will rise in the next quarter as they did during the Great Recession. "In the next quarter, we could see risk assets rally. You could have a feel-good period, and then the reality catches up," Michele said. "If we've been taught anything this month, y
Crude futures were surging Sunday evening after OPEC and its allies announced a surprise production cut.
Treasuries aren't the only refuge in a slowdown. Dividend names also "can provide a margin of safety," says UBS.
Insiders at Peapack-Gladstone and Bankwell Financial scooped up shares in March as the banking sector tanked after SVB’s collapse.
Before she started cash stuffing, Jasmine Taylor said she was tired of being in financial distress. She turned that success into 'Baddies and Budgets'
A growing number of China stocks are setting up or flashing buy signals, as the Chinese economy gains momentum.
Hypotheticals are hard, but what if we considered an alternative world where the Fed had done what critics say should've happened?
Many people dream of owning a chunk of land and putting their dream house on it. Maybe you fantasize about pulling out all the stops and designing a home with every feature you've ever wanted. Well, to make that dream, … Continue reading → The post How to Buy Land and Build Your Dream House appeared first on SmartAsset Blog.
The sum of $10 million might sound like a lot – and to the average person, it is. But what if you want to retire at just 30 years old and potentially live another 40, 50 or even 60 years … Continue reading → The post Is $10 million Enough to Retire at 30? appeared first on SmartAsset Blog.
Tesla deliveries hit a record in Q1, but fell short of views yet again. Tesla stock is up 68% in 2023, breaking out into a buy zone Friday.
Oil prices jumped about $5 a barrel on Monday's open, jolted by a surprise announcement by OPEC+ to cut production further in an effort to support market stability. The Organization of the Petroleum Exporting Countries and their allies including Russia, shook markets by announcing production cuts of about 1.16 million barrels per day on Sunday. The group known as OPEC+ had been expected to maintain its earlier decision to cut output by 2 million bpd until December at its monthly meeting on Monday.
March deliveries from the three Chinese EV makers fell within the companies' guided ranges. Combined deliveries were up month over month and year over year.
